Know Cancer

forgot password

Phase II Trial of Bevacizumab and Satraplatin in Docetaxel Treated Metastatic Androgen Independent Prostate Cancer

18 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

Phase II Trial of Bevacizumab and Satraplatin in Docetaxel Treated Metastatic Androgen Independent Prostate Cancer



- Determine the time to progression in patients with metastatic androgen-independent
prostate cancer previously treated with docetaxel currently treated with satraplatin
and bevacizumab.


- Determine the toxicity of this regimen in these patients.

- Assess the prostate-specific antigen (PSA) response rate in patients treated with this

- Determine the overall survival of patients treated with this regimen.

- Assess changes in levels of N-terminal collagen peptide (NTX) and bone-specific
alkaline phosphatase (BSAP) in patients treated with this regimen.

- Correlate urine NTX and serum BSAP levels with time to progression in patients treated
with this regimen.

OUTLINE: Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral satraplatin on
days 1-5. Treatment repeats every 2 weeks in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed for 28-42 days.

PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.

Inclusion Criteria


- Histologically confirmed adenocarcinoma of the prostate, meeting the following

- Metastatic disease

- Objective progression or rising prostate-specific antigen (PSA) despite
androgen-deprivation therapy and antiandrogen withdrawal

- Patients with rising PSA must demonstrate a rising trend with 2 successive elevations
at a minimum interval of 1 week

- Minimum PSA of 5 ng/mL or new areas of bony metastases on bone scan required if
no measurable disease

- No minimum PSA for measurable disease

- Must have received ≤ 1 prior docetaxel-based chemotherapy for metastatic disease

- No known CNS disease or brain metastases

- Testosterone < 0.5 ng/mL (castrate level)

- Concurrent luteinizing-hormone releasing-hormone agonist allowed to maintain
castrate level


- Zubrod performance status 0-1

- Life expectancy ≥ 12 weeks

- Absolute neutrophil count ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 8.0 g/dL

- Bilirubin normal

- Creatinine ≤ 2 mg/dL OR creatinine clearance ≥ 50 mL/min

- Urine protein:creatinine ratio ≤ 1.0 OR proteinuria ≤ 2+ by urine dipstick OR ≤ 1 g
protein/24-hour urine collection

- Fertile patients must use effective contraception during and for ≥ 6 months after
completion of study treatment

- No significant traumatic injury within the past 28 days

- Adequately controlled hypertension (defined as systolic blood pressure [BP] ≤ 150 mm
Hg and/or diastolic BP ≤ 100 mm Hg on antihypertensive medications)

- No history of hypertensive crisis or hypertensive encephalopathy

- No New York Heart Association class II-IV congestive heart failure

- No myocardial infarction or unstable angina within the past 6 months

- No stroke or transient ischemic attack within the past 6 months

- No significant vascular disease (e.g., aortic aneurysm, aortic dissection)

- No symptomatic peripheral vascular disease

- No evidence of bleeding diathesis or coagulopathy

- No prior malignancy except adequately treated skin cancer or any other cancer in
complete remission for ≥ 2 years

- Able to swallow and retain capsules

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
the past 6 months

- No serious nonhealing wound, ulcer, or bone fracture

- No known hypersensitivity to any component of bevacizumab

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to bevacizumab

- No uncontrolled intercurrent illness, including, but not limited to, any of the

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- No psychiatric illness or social situation that would preclude compliance with study

- No HIV positivity

- No immune deficiency


- See Disease Characteristics

- More than 4 weeks since prior flutamide

- More than 6 weeks since prior bicalutamide or nilutamide

- At least 4 weeks since prior radiotherapy

- At least 2 weeks since prior minor surgery

- More than 7 days since prior core biopsy or minor surgery (excluding placement of a
vascular access device)

- More than 28 days since prior major surgery or open biopsy (8 weeks if high-risk
procedure such as liver resection, thoracotomy, or neurosurgery)

- Concurrent low-dose aspirin (≤ 325 mg/day) allowed

- Concurrent anticoagulants allowed if patient has been on therapy ≥ 4 weeks and has no
acute thromboembolic activity

- No concurrent major surgery

- No concurrent aprepitant

- No concurrent immunosuppressive therapy

- No concurrent combination anti-retroviral therapy for HIV-positive patients

- No other concurrent antitumor therapy (including radiotherapy)

- No other concurrent investigational agents

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to progression

Outcome Time Frame:

Every 70 days

Safety Issue:


Principal Investigator

Ulka N. Vaishampayan, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Barbara Ann Karmanos Cancer Institute


United States: Federal Government

Study ID:




Start Date:

October 2007

Completion Date:

Related Keywords:

  • Prostate Cancer
  • stage IV prostate cancer
  • recurrent prostate cancer
  • adenocarcinoma of the prostate
  • Prostatic Neoplasms



Barbara Ann Karmanos Cancer Institute Detroit, Michigan  48201
Veterans Affairs Medical Center - Detroit Detroit, Michigan  48201-1932